Cellectis

Cellectis is a clinical-stage biotechnology company leveraging its groundbreaking gene-editing platform to develop life-saving cell and gene therapies. Cellectis is pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cell treatments for cancer patients through allogeneic CAR-T immunotherapy in the field of oncology, while also establishing a platform for gene editing in hematopoietic stem cells to treat a variety of diseases. As a clinical-stage biopharmaceutical company with over 24 years of experience and expertise in the field of gene editing, Cellectis is harnessing its TALEN® gene-editing technology and the revolutionary PulseAgile electroporation system to develop life-changing product candidates that tap into the power of the immune system to address unmet medical needs.